Cancer

News

NICE backs chemo-free CLL combination from AbbVie and Roche

Previously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE recommended NHS funding for a combination of AbbVi

News

Merck & Co buys cancer biotech VelosBio for $2.75bn

Merck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion in cash.

News

After two decades, NICE begins consultation on drug assessme...

The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how it assesses medicines, medical devices and diagnostics.

Oncology

Turning patient engagment to patient centricity

Being part of the conversation: Turning patient engagement t...

After three brushes with cancer, Robert Weker understands the patient journey more than many – and he is determined to put that experience to good use.

News

AZ's Q3 results disappoint - but COVID-19 vaccine trial is s...

AstraZeneca has posted an uninspiring set of quarterly results as it gears up for results from its closely watched coronavirus vaccine trial.

News

Europe approves Roche's Tecentriq liver cancer combination

The European Commission has approved Roche’s Tecentriq immunotherapy, in combination with its established cancer drug Avastin, for patients with the most common form of liver cancer.

NICE backs chemo-free CLL combination from AbbVie and Roche

Merck & Co buys cancer biotech VelosBio for $2.75bn

After two decades, NICE begins consultation on drug assessme...

Being part of the conversation: Turning patient engagement t...

AZ's Q3 results disappoint - but COVID-19 vaccine trial is s...

Europe approves Roche's Tecentriq liver cancer combination

Beacon's XLRP gene therapy set for filing after phase 3 win

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks